SLC5A2 and type 2 diabetes mellitus: In the present analysis, we also examined changes in ePV and eEV following initiation of empagliflozin treatment through 24 weeks in order to extend previous findings to patients with type 2 diabetes at high risk of CVD, specifically similar to the previous CVOTs with SGLT2 inhibitors, and to explore mechanisms underlying the early benefit of SGLT2 inhibitors in that patient population.